RKL Wealth Management LLC Has $7.20 Million Stake in Novo Nordisk A/S (NYSE:NVO)

RKL Wealth Management LLC decreased its holdings in Novo Nordisk A/S (NYSE:NVO) by 0.9% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 83,710 shares of the company’s stock after selling 760 shares during the quarter. Novo Nordisk A/S accounts for about 0.6% of RKL Wealth Management LLC’s portfolio, making the stock its 29th largest holding. RKL Wealth Management LLC’s holdings in Novo Nordisk A/S were worth $7,201,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Center for Financial Planning Inc. raised its stake in Novo Nordisk A/S by 72.4% in the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company’s stock worth $25,000 after purchasing an additional 123 shares in the last quarter. Daiwa Securities Group Inc. acquired a new stake in Novo Nordisk A/S in the 3rd quarter worth about $28,000. Capital Performance Advisors LLP bought a new position in Novo Nordisk A/S in the 3rd quarter valued at about $42,000. Albion Financial Group UT increased its holdings in Novo Nordisk A/S by 121.4% in the 4th quarter. Albion Financial Group UT now owns 507 shares of the company’s stock valued at $44,000 after buying an additional 278 shares during the period. Finally, Sound Income Strategies LLC increased its holdings in Novo Nordisk A/S by 82.1% in the 4th quarter. Sound Income Strategies LLC now owns 539 shares of the company’s stock valued at $46,000 after buying an additional 243 shares during the period. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 1.0 %

Shares of Novo Nordisk A/S stock opened at $87.19 on Friday. The firm has a market capitalization of $391.25 billion, a PE ratio of 26.50, a price-to-earnings-growth ratio of 0.90 and a beta of 0.42. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The firm’s 50 day moving average is $84.91 and its 200 day moving average is $105.29. Novo Nordisk A/S has a 1 year low of $77.82 and a 1 year high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Equities research analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The firm also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st will be issued a dividend of $0.7874 per share. This represents a yield of 1.2%. This is a positive change from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date of this dividend is Monday, March 31st. Novo Nordisk A/S’s payout ratio is presently 47.72%.

Analyst Ratings Changes

NVO has been the topic of several recent analyst reports. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. BMO Capital Markets decreased their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, December 23rd. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. Finally, StockNews.com lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. Three investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $145.25.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.